![](/img/cover-not-exists.png)
504 POSTER GA101, a therapeutic glycoengineered CD20 antibody recognizing a type II epitope mediates outstanding anti-tumor efficacy in Non-Hodgkin lymphoma xenograft models and superior B cell depletion
C. Klein, F. Herting, T. Friess, C. Gerdes, A. Nopora, S. Bauer, R. Grau, E. Moessner, J. Dal Porto, P. UmanaVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72438-8
File:
PDF, 59 KB
english, 2008